We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Blood Cell Count Performed at Bedside with Innovative Biochip

By LabMedica International staff writers
Posted on 05 Jan 2016
Print article
Image: Photomicrograph of a blood film showing various leukocytes as part of a differential count (Photo courtesy of the University of Utah).
Image: Photomicrograph of a blood film showing various leukocytes as part of a differential count (Photo courtesy of the University of Utah).
There is a great need for an automated, portable point-of-care blood cell counter that could yield results in a matter of minutes from a drop of blood without any trained professionals to operate the instrument.

Expensive hematology analyzers are currently used as a gold standard for acquiring complete blood cell counts (CBCs) and for nearly all CBCs performed today, the patient must travel to either a hospital with a large laboratory or to a centralized laboratory testing facility.

Scientists at the University of Illinois at Urbana-Champaign (UIUC; Champaign, IL, USA) developed microfluidic biochips capable of a partial CBC using only a drop of whole blood. Total leukocyte and their 3-part differential count are obtained from 10 mL of blood after on-chip lysing of the red blood cells (RBCs) and counting of the leukocytes electrically using microfabricated platinum electrodes. For RBCs and platelets, one mL of whole blood is diluted with phosphate buffered saline (PBS) on-chip and the cells are counted electrically. The total time for measurement is under 20 minutes.

The team is already developing a portable prototype of the cell counter. The base unit of the reader will likely be hand-held and will take cartridges about the size of a credit card. They estimate the cost of a test will be around USD 10 instead of the USD 100 that a current test costs. The technology is scalable and the team also plans to investigate using it in other areas, such as animal diagnostics, blood transfusion analysis, and blood cell counting for managing chemotherapy treatments.

Umer Hassan, PhD, the first author of the study and an expert in bioelectronics, said, “There is huge potential for commercializing the technology and the translation of our technology will result in minimal to no experience requirement for device operation. Even, patients can perform the test at the comfort of their home and share the results with their primary care physicians via electronic means too.” The study was published on December 11, 2015, in the journal Technology.

Related Links:

University of Illinois at Urbana-Champaign 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.